Human skin-resident CD8+T cells require RUNX2 and RUNX3 for induction of cytotoxicity and expression of the integrin CD49aShow others and affiliations
2023 (English)In: Immunity, ISSN 1074-7613, E-ISSN 1097-4180, Vol. 56, no 6, p. 1285-1302.e7Article in journal (Refereed) Published
Abstract [en]
The integrin CD49a marks highly cytotoxic epidermal-tissue-resident memory (TRM) cells, but their differen-tiation from circulating populations remains poorly defined. We demonstrate enrichment of RUNT family tran-scription-factor-binding motifs in human epidermal CD8+CD103+CD49a+ TRM cells, paralleled by high RUNX2 and RUNX3 protein expression. Sequencing of paired skin and blood samples revealed clonal overlap be-tween epidermal CD8+CD103+CD49a+ TRM cells and circulating memory CD8+CD45RA-CD62L+ T cells. In vitro stimulation of circulating CD8+CD45RA-CD62L+ T cells with IL-15 and TGF-b induced CD49a expres-sion and cytotoxic transcriptional profiles in a RUNX2-and RUNX3-dependent manner. We therefore identi-fied a reservoir of circulating cells with cytotoxic TRM potential. In melanoma patients, high RUNX2, but not RUNX3, transcription correlated with a cytotoxic CD8+CD103+CD49a+ TRM cell signature and improved pa-tient survival. Together, our results indicate that combined RUNX2 and RUNX3 activity promotes the differ-entiation of cytotoxic CD8+CD103+CD49a+ TRM cells, providing immunosurveillance of infected and malig-nant cells.
Place, publisher, year, edition, pages
CELL PRESS , 2023. Vol. 56, no 6, p. 1285-1302.e7
National Category
Immunology in the medical area
Identifiers
URN: urn:nbn:se:liu:diva-197435DOI: 10.1016/j.immuni.2023.05.003ISI: 001025956400001PubMedID: 37269830OAI: oai:DiVA.org:liu-197435DiVA, id: diva2:1794077
Note
Funding Agencies|Novartis; European Union Marie Sklodowska-Curie Actions Postdoctoral Fellowship; KI Foundation grant; Swedish Research Council; Ragnar Soederberg Stiftelse; Svenska Lakaresallskapet; Stockholm County Council; Psoriasisfonden; Hudfonden; Swedish Cancer Foundation; Goeran Gustafsson Foundation; Karolinska Institutet Center for Innovative Medicine; Wallenberg Foundation
2023-09-042023-09-042024-05-03